Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial

The Lancet

Volumn 386, Issue 9993, 2015, Pages 552-561

  Bachelez, Hervé ^a   Van De Kerkhof, Peter C M ^b   Strohal, Robert ^c   Kubanov, Alexey ^d   Valenzuela, Fernando ^e,f   Lee, Joo Heung ^g   Yakusevich, Vladimir ^h   Chimenti, Sergio ⁱ   Papacharalambous, Jocelyne ^j   Proulx, James ^j   Gupta, Pankaj ^j   Tan, Huaming ^j   Tawadrous, Margaret ^j   Valdez, Hernan ^j   Wolk, Robert ^j  

^a Universite de Paris Diderot   (France)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Federal Academic Teaching Hospital of Feldkirch   (Austria)

^d Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology   (Russian Federation)

^e HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^f Probity Medical   (Canada)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Solovievs Clinical Hospital for Urgent Medical Care   (Russian Federation)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CREATINE KINASE; ETANERCEPT; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TOFACITINIB; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATOLOGY LIFE QUALITY INDEX; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; EPIDURAL ABSCESS; FEMALE; FOLLOW UP; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON MELANOMA SKIN CANCER; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SYSTEMIC THERAPY; TRANSIENT ISCHEMIC ATTACK; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PSORIASIS; PYRIMIDINES; PYRROLES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84938975662     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62113-9     Document Type: Article

References (33)

1. SR Rapp, SR Feldman, ML Exum, AB Fleischer Jr, DM Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
2. KE Nograles, B Davidovici, JG Krueger New insights in the immunologic basis of psoriasis Semin Cutan Med Surg 29 2010 3 9
3. MA Lowes, AM Bowcock, JG Krueger Pathogenesis and therapy of psoriasis Nature 445 2007 866 873
4. FO Nestle, DH Kaplan, J Barker Psoriasis N Engl J Med 361 2009 496 509
5. RS Stern, KT Nichols, LH Vakeva Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study N Engl J Med 336 1997 1041 1045
6. HM Studniberg, P Weller PUVA, UVB, psoriasis, and nonmelanoma skin cancer J Am Acad Dermatol 29 1993 1013 1022
7. S Hsu, KA Papp, MG Lebwohl et al. Consensus guidelines for the management of plaque psoriasis Arch Dermatol 148 2012 95 102
8. W Weger Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents Br J Pharmacol 160 2010 810 820
9. D Pathirana, AD Ormerod, P Saiag et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris J Eur Acad Dermatol Venereol 23 suppl 2 2009 1 70
10. DS Dubois, R Pouliot Promising new treatments for psoriasis Scientific World J 2013 2013 980419
11. CL Leonardi, AB Kimball, KA Papp et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674
12. KA Papp, RG Langley, M Lebwohl et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
13. MG Lebwohl, H Bachelez, J Barker et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey J Am Acad Dermatol 70 2014 871 881
14. H Yeung, J Wan, AS Van Voorhees et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis J Am Acad Dermatol 68 2013 64 72
15. L Naldi, CE Griffiths Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks Br J Dermatol 152 2005 597 615
16. R Gniadecki, K Kragballe, TN Dam, L Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096
17. M Bonafede, KM Fox, C Watson, N Princic, SR Gandra Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings Adv Ther 29 2012 664 674
18. AW Armstrong, AD Robertson, J Wu, C Schupp, MG Lebwohl Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003-2011 JAMA Dermatol 149 2013 1180 1185
19. BY Chang, F Zhao, X He et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice J Immunol 183 2009 2183 2192
20. KA Papp, A Menter, B Strober et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study Br J Dermatol 167 2012 668 677
21. H Tan, P Gupta, J Harness et al. Dose-response and pharmacokinetics of tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of chronic plaque psoriasis CPT Pharmacometrics Syst Pharmacol 2 2013 e44
22. E Mazzotti, A Picardi, F Sampogna, F Sera, P Pasquini, D Abeni Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis Br J Dermatol 149 2003 318 322
23. CM Mamolo, AG Bushmakin, JC Capelleri Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses J Dermatolog Treat 2014 10.3109/09546634.2014.906033 published online April 11.
24. C Mamolo, J Harness, H Tan, A Menter Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis J Eur Acad Dermatol Venereol 28 2014 192 203
25. L Vijayakrishnan, R Venkataramanan, P Gulati Treating inflammation with the Janus Kinase inhibitor CP-690,550 Trends Pharmacol Sci 32 2011 25 34
26. CL Carroll, SR Feldman, FT Camacho, R Balkrishnan Better medication adherence results in greater improvement in severity of psoriasis Br J Dermatol 151 2004 895 897
27. EE Uhlenhake, D Kurkowski, SR Feldman Conversations on psoriasis - what patients want and what physicians can provide: a qualitative look at patient and physician expectations J Dermatolog Treat 21 2010 6 12
28. CH Smith, AV Anstey, JN Barker et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009 Br J Dermatol 161 2009 987 1019
29. R Fleischmann, J Kremer, J Cush et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N Engl J Med 367 2012 495 507
30. GR Burmester, R Blanco, C Charles-Schoeman et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 381 2013 451 460
31. D van der Heijde, Y Tanaka, R Fleischmann et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study Arthritis Rheum 65 2013 559 570
32. RF van Vollenhoven, R Fleischmann, S Cohen et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N Engl J Med 367 2012 508 519
33. EJ Armstrong, CT Harskamp, AW Armstrong Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies J Am Heart Assoc 2 2013 e000062